These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 1887691)

  • 1. [Discussion comment on the contribution by E. Schulz and H. Remschmidt: Stimulant therapy of hyperkinetic syndrome in childhood and adolescence].
    Bachmann P
    Z Kinder Jugendpsychiatr; 1991 Jun; 19(2):111-3; author reply 114-6. PubMed ID: 1887691
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hyperkinetic syndrome in childhood and adolescence. Diagnosis and therapy].
    Schulz E; Remschmidt H
    Med Monatsschr Pharm; 1991 May; 14(5):137-48. PubMed ID: 1857319
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of stimulant medications in children.
    Morgan AM
    Am Fam Physician; 1988 Oct; 38(4):197-202. PubMed ID: 3051976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulant medication and short attention span: a clinical approach.
    Davy T; Rodgers CL
    J Dev Behav Pediatr; 1989 Dec; 10(6):313-8. PubMed ID: 2513337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stimulant therapy of hyperkinetic syndrome in childhood and adolescence].
    Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr; 1990 Sep; 18(3):157-66. PubMed ID: 1981119
    [No Abstract]   [Full Text] [Related]  

  • 6. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
    Pelham WE; Burrows-Maclean L; Gnagy EM; Fabiano GA; Coles EK; Tresco KE; Chacko A; Wymbs BT; Wienke AL; Walker KS; Hoffman MT
    Exp Clin Psychopharmacol; 2005 May; 13(2):111-26. PubMed ID: 15943544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 8. No correlation between Continuous Performance Test and optimal methylphenidate dosage in ADHD children.
    Chang HL; Ko NC; Liang HY
    Psychiatry Clin Neurosci; 2009 Oct; 63(5):702-3. PubMed ID: 19788634
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder.
    Gulley V; Northup J; Hupp S; Spera S; LeVelle J; Ridgway A
    J Appl Behav Anal; 2003; 36(3):375-8. PubMed ID: 14596580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

  • 11. Is there dose-dependent tolerance associated with chronic methylphenidate therapy in hyperactive children: oral dose and plasma considerations.
    Winsberg B; Matinsky S; Kupietz S; Richardson E
    Psychopharmacol Bull; 1987; 23(1):107-10. PubMed ID: 3602303
    [No Abstract]   [Full Text] [Related]  

  • 12. Another long-acting methylphenidate (Metadate CD).
    Med Lett Drugs Ther; 2001 Oct; 43(1114):83-4. PubMed ID: 11581582
    [No Abstract]   [Full Text] [Related]  

  • 13. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of methylphenidate.
    Daniels SR
    J Pediatr; 2009 Jul; 155(1):A3. PubMed ID: 19559283
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of methylphenidate for attention deficit hyperactivity disorder. Mental Health Committee, Canadian Paediatric Society.
    CMAJ; 1990 Apr; 142(8):817-8. PubMed ID: 2322913
    [No Abstract]   [Full Text] [Related]  

  • 16. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate.
    Barkley RA; DuPaul GJ; McMurray MB
    Pediatrics; 1991 Apr; 87(4):519-31. PubMed ID: 2011430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment.
    Gadow KD; Nolan E; Sprafkin J; Sverd J
    J Dev Behav Pediatr; 1995 Jun; 16(3):167-76. PubMed ID: 7560119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate and chromosome damage.
    Jacobson-Kram D; Mattison D; Shelby M; Slikker W; Tice R; Witt K
    Cancer Lett; 2008 Feb; 260(1-2):216-8. PubMed ID: 18055105
    [No Abstract]   [Full Text] [Related]  

  • 20. [Methylphenidate double-blind trial: indication and performing].
    Bliznakova L; Gerstner S; Schmidt MH; Becker K
    Klin Padiatr; 2007; 219(1):9-16. PubMed ID: 17205427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.